Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer Correspondence
| Author: | Ilson, D. H. |
| Title: | Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer |
| Keywords: | vasculotropin; vascular endothelial growth factor a; overall survival; liver cell carcinoma; note; cancer immunotherapy; practice guideline; vasculotropin inhibitor; risk factor; renal cell carcinoma; monoclonal antibody; protein tyrosine kinase inhibitor; health care quality; cancer inhibition; vasculotropin a; stomach cancer; esophagus cancer; esophagus tumor; esophageal neoplasms; programmed death 1 ligand 1; phase 2 clinical trial (topic); immune checkpoint inhibitor; lenvatinib; humans; human; pembrolizumab; immune checkpoint inhibitors; malignant neoplasm; camrelizumab; rivoceranib |
| Journal Title: | The Lancet Gastroenterology & Hepatology |
| Volume: | 7 |
| Issue: | 3 |
| ISSN: | 2468-1253 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-03-01 |
| Start Page: | 200 |
| End Page: | 201 |
| Language: | English |
| DOI: | 10.1016/s2468-1253(21)00428-3 |
| PUBMED: | 34998470 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Export Date: 1 March 2022 -- Source: Scopus |
